Unknown

Dataset Information

0

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.


ABSTRACT: Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to deliver TC on a dose-dense schedule, with therapy completed within 10 weeks.We enrolled women with early stage breast cancer on a single-arm phase II study of adjuvant dose-dense TC through a regional oncology network. All women completed primary surgery before accrual, and subsequent therapy with TC was deemed appropriate by the treating physician. Planned treatment was docetaxel 75 mg/m(2) plus cyclophosphamide 600 mg/m(2) every 2 weeks for 4 cycles with subcutaneous pegfilgrastim 6 mg administered 24 to 48 hours after the administration of each chemotherapy cycle.Of 42 women enrolled, 41 were evaluable using prespecified criteria. Of these, 37 (90.2%) completed therapy within 10 weeks and 34 (83%) completed therapy at 8 weeks without dose modification. Rates of neuropathy were similar to that reported previously. The rate of neutropenic fever was low (2.5%). Rash and plantar-palmar erythrodythesia were common and reached grade 3 in 4 subjects (9.8%).Dose-dense TC is feasible with tolerability profiles similar to standard TC and a low likelihood of neutropenic fever. This study supports further clinical development of this 8-week adjuvant chemotherapy regimen.

SUBMITTER: Burkard ME 

PROVIDER: S-EPMC4000576 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Burkard Mark E ME   Wisinski Kari B KB   Njiaju Uchenna O UO   Donohue Sarahmaria S   Hegeman Robert R   Stella Amy A   Mansky Patrick P   Shah Varsha V   Goggins Timothy T   Qamar Rubina R   Dietrich Leah L   Kim Kyungmann K   Traynor Anne M AM   Tevaarwerk Amye J AJ  

Clinical breast cancer 20131026 3


<h4>Introduction</h4>Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to deliver TC on a dose-dense schedule, with therapy completed within 10 weeks.<h4>Patients and methods</h4>We enrolled women with early stage breast cancer on a single-arm phase II  ...[more]

Similar Datasets

| S-EPMC7475113 | biostudies-literature
| S-EPMC10361883 | biostudies-literature
| S-EPMC4350798 | biostudies-literature
| S-EPMC6298890 | biostudies-literature
| S-EPMC8025747 | biostudies-literature
| S-EPMC5824321 | biostudies-literature
| S-EPMC4214215 | biostudies-literature
| S-EPMC4552775 | biostudies-literature
| S-EPMC6241678 | biostudies-literature
| S-EPMC7255982 | biostudies-literature